Cargando…

Risk-Adapted Intraoperative Radiation Therapy (IORT) for Breast Cancer: A Novel Analysis

BACKGROUND: Randomized trials have shown that risk-adapted intraoperative radiation therapy (IORT) after breast-conserving surgery for low-risk breast cancer patients is a safe alternative to whole-breast radiation therapy (WBRT). The risk-adapted strategy allows additional WBRT for predefined high-...

Descripción completa

Detalles Bibliográficos
Autores principales: Silverstein, Melvin J., Kim, Brian, Lin, Kevin, Lloyd, Shane, Snyder, Lincoln, Khan, Sadia, Kramme, Katherine, Chen, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495476/
https://www.ncbi.nlm.nih.gov/pubmed/37464138
http://dx.doi.org/10.1245/s10434-023-13897-3
_version_ 1785104904759541760
author Silverstein, Melvin J.
Kim, Brian
Lin, Kevin
Lloyd, Shane
Snyder, Lincoln
Khan, Sadia
Kramme, Katherine
Chen, Peter
author_facet Silverstein, Melvin J.
Kim, Brian
Lin, Kevin
Lloyd, Shane
Snyder, Lincoln
Khan, Sadia
Kramme, Katherine
Chen, Peter
author_sort Silverstein, Melvin J.
collection PubMed
description BACKGROUND: Randomized trials have shown that risk-adapted intraoperative radiation therapy (IORT) after breast-conserving surgery for low-risk breast cancer patients is a safe alternative to whole-breast radiation therapy (WBRT). The risk-adapted strategy allows additional WBRT for predefined high-risk pathologic characteristics discovered on final histopathology. The greater the percentage of patients receiving WBRT, the lower the recurrence rate. The risk-adapted strategy, although important and necessary, can make IORT appear better than it actually is. METHODS: Risk-adapted IORT was used to treat 1600 breast cancers. They were analyzed by the intention-to-treat method and per protocol to better understand the contribution of IORT with and without additional whole-breast treatment. Any ipsilateral breast tumor event was considered a local recurrence. RESULTS: During a median follow-up period of 63 months, local recurrence differed significantly between the patients who received local treatment and those who received whole-breast treatment. For 1393 patients the treatment was local treatment alone. These patients experienced 79 local recurrences and a 5-year local recurrence probability of 5.95 %. For 207 patients with high-risk final histopathology, additional whole-breast treatment was administered. They experienced two local recurrences and a 5-year local recurrence probability of 0.5 % (p = 0.0009). CONCLUSIONS: Whole-breast treatment works well at reducing local recurrence, and it is a totally acceptable and necessary addition to IORT as part of a risk-adapted program. However, the more whole-breast treatment that is given, the more it dilutes the original plan of simplifying local treatment and the less we understand exactly what IORT contributes to local control as a stand-alone treatment.
format Online
Article
Text
id pubmed-10495476
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-104954762023-09-13 Risk-Adapted Intraoperative Radiation Therapy (IORT) for Breast Cancer: A Novel Analysis Silverstein, Melvin J. Kim, Brian Lin, Kevin Lloyd, Shane Snyder, Lincoln Khan, Sadia Kramme, Katherine Chen, Peter Ann Surg Oncol Breast Oncology BACKGROUND: Randomized trials have shown that risk-adapted intraoperative radiation therapy (IORT) after breast-conserving surgery for low-risk breast cancer patients is a safe alternative to whole-breast radiation therapy (WBRT). The risk-adapted strategy allows additional WBRT for predefined high-risk pathologic characteristics discovered on final histopathology. The greater the percentage of patients receiving WBRT, the lower the recurrence rate. The risk-adapted strategy, although important and necessary, can make IORT appear better than it actually is. METHODS: Risk-adapted IORT was used to treat 1600 breast cancers. They were analyzed by the intention-to-treat method and per protocol to better understand the contribution of IORT with and without additional whole-breast treatment. Any ipsilateral breast tumor event was considered a local recurrence. RESULTS: During a median follow-up period of 63 months, local recurrence differed significantly between the patients who received local treatment and those who received whole-breast treatment. For 1393 patients the treatment was local treatment alone. These patients experienced 79 local recurrences and a 5-year local recurrence probability of 5.95 %. For 207 patients with high-risk final histopathology, additional whole-breast treatment was administered. They experienced two local recurrences and a 5-year local recurrence probability of 0.5 % (p = 0.0009). CONCLUSIONS: Whole-breast treatment works well at reducing local recurrence, and it is a totally acceptable and necessary addition to IORT as part of a risk-adapted program. However, the more whole-breast treatment that is given, the more it dilutes the original plan of simplifying local treatment and the less we understand exactly what IORT contributes to local control as a stand-alone treatment. Springer International Publishing 2023-07-18 2023 /pmc/articles/PMC10495476/ /pubmed/37464138 http://dx.doi.org/10.1245/s10434-023-13897-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Breast Oncology
Silverstein, Melvin J.
Kim, Brian
Lin, Kevin
Lloyd, Shane
Snyder, Lincoln
Khan, Sadia
Kramme, Katherine
Chen, Peter
Risk-Adapted Intraoperative Radiation Therapy (IORT) for Breast Cancer: A Novel Analysis
title Risk-Adapted Intraoperative Radiation Therapy (IORT) for Breast Cancer: A Novel Analysis
title_full Risk-Adapted Intraoperative Radiation Therapy (IORT) for Breast Cancer: A Novel Analysis
title_fullStr Risk-Adapted Intraoperative Radiation Therapy (IORT) for Breast Cancer: A Novel Analysis
title_full_unstemmed Risk-Adapted Intraoperative Radiation Therapy (IORT) for Breast Cancer: A Novel Analysis
title_short Risk-Adapted Intraoperative Radiation Therapy (IORT) for Breast Cancer: A Novel Analysis
title_sort risk-adapted intraoperative radiation therapy (iort) for breast cancer: a novel analysis
topic Breast Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495476/
https://www.ncbi.nlm.nih.gov/pubmed/37464138
http://dx.doi.org/10.1245/s10434-023-13897-3
work_keys_str_mv AT silversteinmelvinj riskadaptedintraoperativeradiationtherapyiortforbreastcanceranovelanalysis
AT kimbrian riskadaptedintraoperativeradiationtherapyiortforbreastcanceranovelanalysis
AT linkevin riskadaptedintraoperativeradiationtherapyiortforbreastcanceranovelanalysis
AT lloydshane riskadaptedintraoperativeradiationtherapyiortforbreastcanceranovelanalysis
AT snyderlincoln riskadaptedintraoperativeradiationtherapyiortforbreastcanceranovelanalysis
AT khansadia riskadaptedintraoperativeradiationtherapyiortforbreastcanceranovelanalysis
AT krammekatherine riskadaptedintraoperativeradiationtherapyiortforbreastcanceranovelanalysis
AT chenpeter riskadaptedintraoperativeradiationtherapyiortforbreastcanceranovelanalysis